STOCKS TELEGRAPH

Tag: TNXP Stock Price

  • Tonix Pharmaceuticals (TNXP) Stock Surges Following FDA Regulatory Update

    Tonix Pharmaceuticals (TNXP) Stock Surges Following FDA Regulatory Update

    After a major regulatory update, Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) saw a sharp increase in the value of its shares. TNXP shares were up 35.02% to $31.10 as of the most recent market check. The spike comes after the business revealed that TNX-102 SL, its experimental fibromyalgia therapy, is being reviewed by regulators.

    The FDA Removes the Need for an Advisory Committee Assessment

    Tonix Pharmaceuticals stated that the FDA has decided not to convene an Advisory Committee meeting to review the company’s New Drug Application (NDA) for TNX-102 SL, a sublingual form of cyclobenzaprine hydrochloride. If approved, TNX-102 SL would be the first new pharmacological treatment for fibromyalgia in 15 years, providing millions of patients with the ailment with a new therapeutic option.

    Understanding Fibromyalgia’s Effects

    Central sensitization, in which the central nervous system amplifies pain and sensory impulses, is a characteristic of fibromyalgia, a widespread chronic pain disorder. Neuroimaging studies have revealed significant functional abnormalities in the insula and anterior cingulate cortex of the brain.

    The illness affects more than 10 million persons, with a greater frequency among women. Fatigue, non-restorative sleep, chronic, pervasive discomfort, and cognitive impairment—often referred to as “brain fog”—are typical symptoms. Furthermore, psychological issues including anxiety, sadness, headaches, and gastrointestinal distress are frequently linked to fibromyalgia.

    Route to Possible Market Introduction

    The FDA’s trust in the current clinical evidence supporting TNX-102 SL is indicated by the lack of an Advisory Committee requirement. TNXP anticipates the medication to possibly go on sale in Q4 2025, pending regulatory approval.

    TNX-102 SL would introduce a novel class of medications specifically made to treat fibromyalgia if it were authorized. In 2024, the company already received a Fast Track designation for TNX-102 SL. For drugs that address critical medical needs, this FDA initiative speeds up the review process.

    This regulatory milestone further demonstrates Tonix Pharmaceuticals’ commitment to addressing unmet medical needs in chronic pain management and positioned the firm for a major advancement in the therapeutic landscape for fibromyalgia.

  • Tonix Pharmaceuticals (TNXP) Stock Rises Sharply After Key Event Announcements

    Tonix Pharmaceuticals (TNXP) Stock Rises Sharply After Key Event Announcements

    Following the announcement that Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) will be attending a big investor event, the company’s stock value surged sharply. The most recent market report showed that TNXP shares were up 17.45% at $9.16.

    Attending Investor Summits

    Tonix Pharmaceuticals (TNXP) announced that on Tuesday, March 11, 2025, its Chief Operating Officer, Jessica Morris, would appear at the 2025 Virtual Investor Summit. This strategic move is expected to boost investor confidence and highlight the business’s latest advancements in fibromyalgia therapy.

    Novel Approaches to Fibromyalgia Research

    Tonix Pharmaceuticals recently provided positive data at the 7th International Congress on Controversies in Fibromyalgia, held March 3–4, 2025, in Vienna, Austria. The company released data on TNX-102 SL, an investigational treatment for fibromyalgia.

    In contrast to conventional oral cyclobenzaprine, which has not shown long-term efficacy, TNX-102 SL showed statistically significant and sustained pain alleviation in two Phase 3 clinical trials. Given the chronic nature of fibromyalgia, it is imperative to find long-lasting therapeutic options, and TNX-102 SL may significantly enhance patient care.

    FDA Decision Awaiting

    The U.S. Food and Drug Administration (FDA) has set August 15, 2025, as the Prescription Drug User Fee Act (PDUFA) goal date for TNX-102 SL’s marketing authorization determination. If approved, it would be the first novel treatment for fibromyalgia in fifteen years, offering patients who have been suffering from chronic pain a state-of-the-art option. 

    A New Method for Drug Delivery Increases Efficiency

    TNX-102 SL’s sublingual formulation facilitates rapid transmucosal absorption while avoiding first-pass hepatic metabolism. This method raises the bioavailability of cyclobenzaprine by decreasing the formation of norcyclobenzaprine (norCBP), a metabolite associated with reduced efficacy in oral formulations.

    The drug successfully met its main goals by significantly reducing daily pain levels when compared to a placebo. Additionally, the drug was generally well tolerated, and clinical testing showed no new safety issues. Tonix Pharmaceuticals’ TNX-102 SL has a lot of promise to address the long-standing unmet needs of fibromyalgia patients, and regulatory approval is quickly approaching.

  • Here is why Tonix Pharmaceuticals Holding Corp. (TNXP) stock plummeted on Friday?

    TNXP stock closed Friday, July 23, 2021 at $0.98. Earlier in the morning session on Monday, TNXP shares lost 34.18% at $0.64. Tonix Pharmaceuticals Holding Corp. (TNXP) shares have fallen 35.10% over the last 12 months, and they have moved up 0.04% in the past week. Over the past three months, the stock has lost 5.77%, while over the past six months, it has shed 4.85%.

    Let’s have a brief look at its recent news and developments.

    Negative Results of Interim Analysis of Phase 3 Study of TNX-102 SL

    On July 23, 2021, Tonix Pharmaceuticals Holding Corp (TNXP)  decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC) of the RALLY study.

    IDMC recommended stopping the trial for futility, after the interim analysis results of the first 50% enrolled participants as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those treated with TNX-102 SL 5.6 mg (2x 2.8 mg tablets) and those receiving placebo.

    TNXP New board member appointment

    Tonix Pharmaceuticals Holding Corp appointed Carolyn E. Taylor to its Board of Directors, effective as of July 16, 2021.

    TNXP Inauguration to Russell 2000® and Russell 3000® Indexes

    TNXP stock was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opened on June 28, 2021, as part of the annual reconstitution of the Russell stock indexes.

    Treatment for Long COVID Syndrome

    On June 21, 2021, Tonix Pharmaceuticals Holding Corp (TNXP) announced its plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID) which is now known officially as Post-Acute Sequelae of COVID-19 (PASC).

    Tonix plans to meet with the U.S. Food and Drug Administration (FDA) in the third quarter of 2021 to seek agreement on the design of a potential Phase 2 pivotal study and the overall clinical development plan to qualify TNX-102 SL as an indicated treatment for Long COVID.

    Participation in the conferences

    Tonix (TNXP) recently participated in the BIO Digital Conference which was held on June 10-11 and 14-18, 2021. The company was presented by Seth Lederman, M.D., President and Chief Executive Officer of Tonix.

    The company also participated in the Raymond James Human Health Innovation Conference which was held on June 23, 2021.

    Conclusion

    The company’s recent announcement about halting the enrolment in TNX-102 SL trials due to negative outcomes was the reason behind its significant loss on Friday. TNXP can continue to decline in the coming days as well.

  • Tonix Pharmaceuticals Holding Corp. (TNXP) surged in the premarket trading session; find out why

    Tonix Pharmaceuticals Holding Corp. (TNXP) surged in the premarket trading session; find out why

    In premarket trading session, Tonix Pharmaceuticals Holding Corp. (TNXP) stock had surged by 2.46% to $1.25 at last check. TNXP stock previously closed the session at $1.22 on Friday. The stock volume traded 5.76 million shares. In the past year up to date TNXP stock have risen by 93.01% however in the past week they shed by -8.27%. In the past three and six months, the TNXP stock had plunged -15.86%, while adding 109.44% respectively. Furthermore, Tonix Pharmaceutical is currently valued in the market at $401.70 million and has 326.51 million outstanding shares.

    Here’s what you need to know about TNXP stock

    Tonix Pharmaceutical Holding  Corp, is a clinical stage biopharma company that specifically focuses on the treatments and prevention of human diseases along with the alleviation of the pain and wounds. TNXP stock does this through developing and licensing small molecules and biologics for prevention of infectious diseases. Furthermore, the company addresses a certain immunosuppression which can aggravate the immune fight response of the body, autoimmune diseases and cancer. Furthermore, the company focuses on the treatment of pain, neurologic, psychiatric and addiction conditions through its proprietary design and manufacturing of leading candidates.

    Currently the company’s lead vaccine candidate is TNX-1800 which is a live replicating version of vaccine that instills the horsepox viral vector as a platform to protect against the COVID-19. Furthermore the company has other vaccine candidates that also replicate the same horsepox live vaccine virus to serve as a vector platform and prevent against monkeypox, smallpox and COVID-19 prevention. Its items incorporate TNX-1300 for the treatment of cocaine inebriation; TNX-601 CR for despondency problem, PTSD, and neurocognitive brokenness from corticosteroids; and TNX-1900 for headache and craniofacial torment treatment. Its preclinical pipeline incorporates TNX-1600 for PTSD, despondency, and consideration shortfall hyperactivity issue; TNX-1700 for gastric and pancreatic malignant growths; TNX-701 for radioprotection; TNX-1200, a smallpox immunization; TNX-1500, a monoclonal counter acting agent against CD40-L for organ relocate dismissal autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi disorder. It additionally creates TNX-2100, a COVID-19 skin test. It has cooperation concurrences with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The organization was fused in 2007 and is settled in Chatham, New Jersey.

    The long term potential of TNX-102 as COVID treatment

    TNXP stock had announced today that it is aiming to develop the TNX-102 SL for potential treatment of long Covid Syndrome. This condition is officially known as Post-Acute Sequelae of Covid-19 (PASC). The CNS candidate is also for the treatment of aggravated Alzheimer disease, PTSD, and alcohol disorder, known as TNX-102 SL which is formulation of cuclobenzaprine in sublingual tablets for the treatment of fibromyalgia as well.

    In the third quarter of 2021, there will be meeting with the U.S Food and Drug Administration for the potential design of the Phase 2 study of TNX-102 SL which will be pivotal for the overall clinical development of the CNS candidate for its further indicated use as Long COVID treatment.TonixPharamceuticals Holding Corp. found out about the pharmacodynamic movement of TNX-102 SL from more than 1,000 members who have been or are taken on its fibromyalgia preliminaries to date. Long COVID has been contrasted with fibromyalgia as a result of the normal indications of rest unsettling influence, diligent torment, weariness, and cerebrum haze.

    TNX-102 SL is in mid-Phase 3 advancement for the treatment of fibromyalgia, for which between time examination aftereffects of the second potential significant investigation are expected in the second from last quarter of 2021, and topline results are in the principal quarter of 2022.

  • Tonix Pharmaceuticals (TNXP) Continues to Rally after licensing Technology for Willi Syndrome

    Tonix Pharmaceuticals (TNXP) Continues to Rally after licensing Technology for Willi Syndrome

    Tonix has licensed technology from the French National Institute of Health and Medical Research (Inserm).

    Shares of Tonix Pharmaceuticals (TNXP) have since the start of February 2021. On Monday, the shares soared over 22% following the announcement to develop a COVID-19 skin test. Once again, the stock is rolling, but this time with another important achievement. The company just announced that it has obtained a license from the French National Institute of Health and Medical Research to treat patients with Willi Syndrome.

    Another reason why investors might be enthused is Tonix’s treatment for agitation in Alzheimer’s disease. So, there has been a lot happening and the drugmaker has a big upside with all the substantial projects on-hand.

    What’s Next?

    Tonix Pharmaceuticals (TNXP) stock has skyrocketed up to 16.26% to $1.89, as we write this. The penny stock has been trading above $1 one on consistently during this month, followed by several developments happening around.

    The company has obtained the green signal to begin work on the treatment of Prader-Willi syndrome, which constantly causes hunger and leads to severe obesity resulting in various health issues.

    The co-exclusive license will allow the company to design its program more broadly, with the product being designated as TNX-2900. The patents covering the feature technology for Willi syndrome is available for the company across the US and Europe via the co-licensees till 2031. Tonix plans to get in contact with the FDA for submitting an application for TNX-2900 for Fast Track designation and Orphan Drug.

    Another major project that the company is currently working on it’s the diagnostic skin test for testing the COVID-19 virus. Tonix intends to initiate the development of the skin test, called TNX-2100 that will measure T-cell immunity to SARS-CoV-2. According to the researchers, T-cell immunity is an important factor that could help in protecting from severe variants of the coronavirus.

    Furthermore, the company is also working on its lead product for Alzheimer’s Disease. Tonix has filed the patent for its TNX-102 SL. If the company obtains the patent it will begin working on the product, which would be a big achievement for the company—taking it one step close to Alzheimer’s Disease solution. Millions of Americans suffer from this disease each year and yet, we do not have any FDA-approved drug for Alzheimer’s.

    Above all, the company closed its registered direct offering worth $70 million. Tonix sold more than 53 million common stock shares at $1.20 per share to generate the gross proceeds. The company will use the funding to finance TNX-2100 and other clinical projects.

    Conclusion

    Tonix Pharmaceuticals (TNXP) has been on the higher side in the past couple of weeks. TNXP’s shares price would ride back to its normal once the near-term upside is achieved. However, the clinical projects under development are real assets for the company that could be a blockbuster in the long-term.